Compare Stryker Corporation (SYK) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stryker Corporation vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? Stryker Corporation trades at $315.34 (market cap $122.35B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. The key difference: Stryker Corporation pays a 1% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none, and Stryker Corporation is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| SYK | VCIT | |
|---|---|---|
Market Cap | $122.35B | — |
Sector | Technology | Fixed Income |
52-Week High | $403.53 | $84.82 |
52-Week Low | $282.58 | $81.45 |
Enterprise Value | $134.10B | — |
Dividend Yield | 1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stryker (SYK) trades at $319.14, down 0.23% on the day, with a bearish technical signal despite strong fundamentals. The company reported $25.12B revenue and $3.25B net income for 2025, maintaining robust profitability with 63.83% gross margins and 13.21% net margins. Recent Q1 2026 earnings missed expectations due to a cybersecurity disruption, but management maintained full-year guidance. Analyst consensus remains strongly bullish with a $388.44 price target and 74% buy ratings.
The stock presents a compelling opportunity for long-term investors given its strong fundamentals and innovation pipeline, though near-term technical weakness and competitive pressures warrant caution. Upside potential exists from continued Mako robotics adoption and market share gains, while risks include cybersecurity vulnerabilities and integration challenges from acquisitions.
VCIT trades at $81.71, down 0.28% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF maintains consistent dividend distributions, with recent payouts of $0.33-$0.34, reflecting its income-focused strategy. News coverage highlights VCIT's competitive expense ratio of 0.03% and yield advantages over peers like VGIT and IEI, though technical indicators suggest near-term pressure with support clustered around $82.
The outlook balances VCIT's low-cost access to intermediate-term corporate bonds against interest rate sensitivity and economic cycle risks. Current bearish momentum warrants caution, but the fund's structural efficiency and yield appeal position it for income investors seeking diversified credit exposure amid fluctuating fixed-income conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
